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Abstract
 .Group II phospholipase A sPLA has been implicated as an important agent involved in a number of inflammatory2 2
 .  .processes. Potent pro-inflammatory cytokines, such as interleukin-1b IL-1b and tumor necrosis factor TNF have been
found to induce sPLA synthesis and release from many cell types among which mesangial cells. Although considerable2
research has been devoted to unravelling the mechanisms underlying the induction of sPLA not much is known about the2
time scale at which the cytokine elicited signals for sPLA induction persist in target cells. In this study we addressed that2
question by using rat renal mesangial cells as a model target cell. We found that after removal of IL-1b from the culture
medium, the induced-sPLA synthesis continues at gradually decreasing rates for approximately 8 h. This is accompanied2
by a decrease in sPLA mRNA levels. Furthermore, with pulse-chase experiments we investigated the half-life of sPLA2 2
disappearance from the cells. This disappearance was found to be biphasic. A rapidly disappearing pool, constituting
approx. 74% of the total, exhibited a half-life of 1.6"0.2 h. The remaining pool of the induced enzyme was much more
stable and its level remained constant for at least 24 h. Analysis of the appearance of newly synthesized enzyme in the
culture medium indicated this process to be completed in an hour.
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1. Introduction
 .Phospholipase A PLA is a key enzyme in the2 2
formation of lipid mediators. By hydrolyzing the
phospholipids of the cell membrane it releases both
arachidonic acid, the precursor for eicosanoids, and
lysophospholipids including 1-O-alkyl-sn-glycero-3-
Abbreviations: IL-1b , interleukin-1b ; TNF, tumor necrosis
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phosphocholine, the precursor for platelet-activating
w xfactor 1 . At present, three main groups of mam-
malian PLA s have been described, i.e. two low2
 .molecular weight 14 kDa PLA s and a high molec-2
w xular weight PLA of 85 kDa 2,3 . The 85 kDa PLA2 2
is mainly located in the cytoplasma in a variety of
w xcells and tissues among which mesangial cells 4,5 .
This enzyme shows a preference for substrates con-
taining arachidonic acid esterified at the sn-2 position
of phospholipids and becomes translocated to mem-
w xbranes in a calcium-dependent manner 6 . Mam-
malian group I PLA is mainly expressed in the2
pancreas and it has long been thought to act only as a
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w xdigestive enzyme 7 . However, several reports have
documented the existence of pancreatic group I PLA 2
w xin other tissues such as spleen, lung 8 and kidney
w x9 , but the role of this extrapancreatic enzyme is not
clear. Mammalian group II PLA , also referred to as2
sPLA , is expressed in many tissues and is found2
abundantly in soluble form at inflammatory sites
w x10–12 and circulating in the plasma of patients with
w xvarious inflammatory diseases 13 suggesting a role
for this enzyme in inflammatory processes. This idea
is supported by observations showing that inflamma-
tion can be induced in animals by injection of sPLA 2
w x14–16 . However, induction of inflammation has not
always been observed with the purified enzyme and
w xmay require additional pro-inflammatory factors 17 .
Group II PLA is secreted by a large number of2
cell types in which the expression is strongly upregu-
lated by pro-inflammatory cytokines such as TNF,
IL-1b and IL-6. IL-1 and TNF stimulate PLA syn-2
w xthesis and secretion in rabbit chondrocytes 18 , rat
w xmesangial cells 19,20 , rat vascular smooth muscle
w x w xcells 21 , rat calvarial osteoblasts 22 and astrocytes
w x23 . It is also demonstrated that IL-6, alone or in
combination with TNF and IL-1, stimulates PLA 2
w xsynthesis in human HepG2 cells 24 . High amounts
of PLA were found in synovial fluid of patients with2
w xrheumatoid arthritis 11 and in plasma of patients
w x w xwith septic shock 25,26 , malaria 13 , pancreatitis
w x w x27 , adult respiratory distress syndrome 28 , typhoid
w xfever 29 , acute chest syndrome of sickle cell disease
w x w x30 and following therapy with IL-2 31 . In all cases
the increased plasma PLA activity was immunologi-2
cally characterised as group II sPLA , and when2
investigated in serial plasma samples, sPLA peak2
levels followed those of TNF, IL-1 and IL-6
w x13,29,31 . Based on the induction and secretion of
the enzyme by cytokines from HepG2 liver cell line
sPLA has been recognised as an acute phase protein2
w xsecreted by the liver 24 , but the exact cellular origin
of circulating sPLA remains often unknown and2
other target cells, mentioned above, that respond to
cytokines by sPLA secretion are likely to contribute2
as well.
While mechanisms of induction and synthesis of
sPLA are gradually being explored and the inhibi-2
tion of this enzyme by different agents is intensively
studied at present, less is known about the time scale
at which the cytokine-induced signals for sPLA 2
synthesis and secretion from target cells remain ac-
tive after the levels of proinflammatory cytokines
decrease to normal. In order to get further insight in
these processes we investigated the production and
disappearance of the enzyme in cultured rat renal
mesangial cells as function of time after removal of
the IL-1b signal by measuring the sPLA activity2
and antigen levels. Since it is well established that in
these cells, as in most other target cells, the IL-1b-in-
duced sPLA synthesis follows elevated steady-state2
w xlevels of sPLA mRNA 32,33 , the effect of with-2
drawal of the IL-1b signal on these sPLA mRNA2
levels in time was analyzed by Northern blotting. The
half-life of sPLA in IL-1b-stimulated mesangial2
cells and the rate of secretion of the enzyme into the
culture medium was explored in pulse-chase experi-
ments.
2. Materials and methods
2.1. Materials
X w 32 x wDeoxycytidine 5 - a- P triphosphate a-
32 x . w 14 xP dCTP, 3000 Cirmmole , 1- C linoleic acid and
w 35 x w 35 xL- S methioninerL- S cysteine were obtained
from Amersham International, UK. Protein A-Sep-
 .harose Cl-4B was a product from Pharmacia
Biotech, Uppsala, Sweden. IL-1b was prepared by
the Biotechnology Department of Ciba Geigy, Basel,
Switzerland. Nitrocellulose and Nytran nylon mem-
brane were obtained from Schleicher and Schuell,
Dassel, FRG. The Decaprimed labeling kit was a
product from Ambion, Austin, USA.
2.2. Methods
2.2.1. Cell culture and incubation
Cultivation and characterisation of rat mesangial
w xcells was performed as described previously 34 .
Briefly, the cells were grown in RPMI 1640 supple-
mented with 10% fetal calf serum, penicillin 100
.  .Urml , streptomycin 100 mgrml , and bovine in-
sulin at 0.66 Urml. For the experiments passages
8-20 were used. Confluent mesangial cells cultured in
60 mm dishes were rinsed once with PBS and incu-
bated with 1.5 ml serum-free medium containing 0.1
 .mgrml fatty acid-free bovine serum albumin Sigma
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and stimulated with IL-1b for 18 h. For Northern
blot experiments 75 cm2 flasks were used.
2.2.2. PLA assay2
PLA activity was assayed using 0.2 mM sn2-2
w 14 xlabeled 1- C linoleoylphosphatidylethanolamine
 .specific activity 3000 dpmrnmol in 0.2 ml of 0.1
M TrisrHCl, pH 8.5, in the presence of 10 mM
CaCl . Reactions were stopped after 30 min and the2
liberated 14C-labeled fatty acids were extracted by a
w xmodified Dole extraction procedure 35 . The sub-
w 14 xstrate 1-acyl-2 1- C linoleoylphosphatidylethanol-
w xamine was prepared as described previously 35 .
2.2.3. Immunoblotting
SDS-polyacrylamide gel electrophoresis using a
15% polyacrylamide gel was done according to
w xLaemmli 36 at a constant voltage of 200 V. For
immunoblotting the proteins were transferred to
nitrocellulose during 1.5 h with 2 mArcm2. Nonspe-
 .cific binding sites were blocked with 0.1% wrv
milkpowder in phosphate-buffered saline for 45 min
at room temperature followed by incubation with
primary antibody, i.e. a 1:60 dilution of each of the
w xhybridoma supernatants 2E7 and 2B9 37 in 0.01%
milk powder. After the primary antibody incubation
the blot was incubated with alkaline phosphatase
conjugated goat anti-mouse IgG. After washing the
alkaline phosphatase activity was detected by devel-
oping the blots in p-nitroblue tetrazolium and 5-
bromo-4-chloro-3-indolyl-phosphate.
2.2.4. Northern-blot analysis
Total mesangial cell RNA was extracted using the
guanidinium thiocyanaterphenolrchloroform method
w x38 . The RNA was precipitated with isopropyl alco-
hol and the pellets were washed with 75% ethanol.
Samples of 20 mg RNA were separated on 0.8%
agarose gels containing 6.6% formaldehyde and
transferred onto Nytran nylon membrane using a
turbo-blot system of Schleicher and Schuell. The
RNA was fixed to the membrane by 3 min treatment
 . w xin a microwave oven at full setting 650 W 39 and
 .prehybridized for about 4 h at 428C in 50% vrv
 .formamide, 10% wrv dextrane sulphate, 1% SDS
 .wrv , 1 M NaCl and 100 mgrml denatured herring
sperm DNA. Thereafter, the filters were hybridized at
w x428C overnight with rat group II PLA cDNA 402
w 32 xlabeled with a- P dCTP according to the random
primed labeling technique described by Feinberg and
w xVogelstein 41 . Finally, the filters were washed sev-
eral times in 2=SSCr1% SDS. The signal was
detected by autoradiography. The ribosomal RNA
w xwas stained on the filters with methylene blue 42 in
order to asses equal RNA loading and transfer.
2.2.5. Cell labeling and immunoprecipitation
Cells were grown in 60 mm culture dishes and
incubated with IL-1b as described above. Next, the
medium was withdrawn and the cells were preincu-
bated for 20 min with methionine- and cysteine free
medium containing 0.1 mgrml BSA in the presence
 .of IL-1b 1 nM . Thereafter, the cells were pulsed
for 2 h with the same medium containing L-
w 35 x w 35 x S methioninerL- S cysteine 200 mCirdish,
.spec. act. )1000 Cirmmol . Chases were initiated
 .by adding cycloheximide 20 mM and cold methion-
ine and cysteine, up to a concentration of 1.5 mM
and 1.25 mM, respectively. Following aspiration of
the media, the cells were washed twice with ice-cold
phosphate-buffered saline and scraped into 500 ml of
cold radioimmunoprecipitation assay buffer RIPA,
20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM
EDTA, 1 mM PMSF, 5 mM benzamidine, 50 mM
.NaF, 250 mM Na VO and 10 mM Na HPO . The3 4 2 4
lysates were centrifuged at 100 000=g for 30 min at
 .48C Beckman TLA 100 ultracentrifuge to remove
unsolubilized material and the supernatants were
transferred to an other tube and used for immuno-
precipitation. The samples were incubated at 48C
w xovernight with a specific monoclonal antibody 37
against rat group II PLA in the presence of 0.5 M2
salt. The sPLA -antibody complex was removed by2
1-h incubation with 6 mg of protein A-Sepharose.
The immunoprecipitate was washed twice with a high
salt buffer 20 mM TrisrHCl, pH 7.4, 0.5 M NaCl,
.1% Triton X-100 and twice with a low salt buffer
20 mM TrisrHCl, pH 7.4, 0.15 M NaCl, 1% Triton
.X-100 . The samples were boiled for 5 min in 30 ml
of Laemmli’s sample buffer and applied to SDS-
 .PAGE 15% gel . Gels were fixed, soaked in amplify
 .Amersham for 20 min, dried and exposed to a film
at y708C. For quantitative determinations appropri-
ate gel areas were cut out and counted in a liquid
scintillation counter.
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3. Results
3.1. Le˝els of sPLA protein and mRNA in mesangial2
cells after withdrawal of IL-1b
Cytokines, such as TNF and IL-1, induce the
synthesis of sPLA , but the duration at which the2
signals remain operative is unknown. To get more
insight in these events the net effect of ungoing
production and secretion of the enzyme after with-
drawal of IL-1b from rat mesangial cells was stud-
ied. For this purpose the cells were stimulated
overnight with IL-1b , whereafter the cells were
placed on medium without this cytokine. At different
time points medium and cells were collected and
assayed for PLA activity. Total sPLA activity was2 2
 .plotted against time Fig. 1 . For the media the
activities that were already present in the media
removed after overnight stimulation were added to
the activities found at each time point. As can be seen
from Fig. 1, the activity and protein levels in the
medium increases up to about 8 h, whereas in the
homogenate hardly any increase can be seen. This
can be explained by the fact that more than 80% of
the induced sPLA is secreted into the culture2
Fig. 1. Time course of total sPLA levels in medium and cells2
after withdrawal of IL-1b. Rat mesangial cells were stimulated
 .for 18 h with IL-1b 1 nM . Thereafter, the medium was
replaced by medium without IL-1b and after different incubation
periods the cells were scraped in homogenization buffer. The
sPLA activities were determined in aliquots of both the culture2
 .  .medium ’ and cell homogenates e and are expressed as total
 .sPLA activities"S.D. ns4 . For Western blotting 800 ml of2
medium was used and a representative blot is shown.
Fig. 2. Time-course of sPLA mRNA levels in mesangial cells2
after withdrawal of IL-1b. Mesangial cells were incubated for 18
 .  .h with IL-1b 1 nM or vehicle con . Thereafter, the medium
was replaced by medium without IL-1b and at different time
 .points RNA was isolated. Total RNA 20 mg was hybridized to
a
32P-labeled sPLA probe. With methylene blue 28S RNA was2
stained on the filters in order to assess equal RNA loading.
w x medium 20 compare also the sPLA activities in2
.cells and medium at zero time in Fig. 1 . To investi-
gate whether changes in sPLA protein synthesis2
were paralleled by equivalent changes in sPLA 2
mRNA levels we performed Northern blot analysis.
Mesangial cells were treated in the same manner as
described in the previous experiment. As shown in
Fig. 2 sPLA mRNA steady state levels are elevated2
upon stimulation with IL-1b compared to control.
Levels of sPLA mRNA decrease in a time-depen-2
dent manner after IL-1b is removed. These changes
in mRNA levels are in agreement with the decrease
in sPLA steady-state levels as shown in Fig. 1.2
3.2. Half-life of IL-1b-induced sPLA in mesangial2
cells
Next we wanted to determine the half-life of the
sPLA enzyme in rat mesangial cells. In order to do2
this pulse-chase experiments were performed. In ini-
tial experiments cells were chased by replacing the
medium with medium containing a large excess of
unlabeled methionine and cysteine without addition
of the protein synthesis inhibitor cycloheximide, in
order to change the culture conditions as little as
possible. However, under these conditions radioac-
tively labeled sPLA remained to be synthesized2
during the initial phase of the chase period as evi-
denced by the 2-fold increase in radioactivity in the
 .enzyme up to 1 h Fig. 3 compared to that found at
 .time-point zero Fig. 3 . Most likely, there are still
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Fig. 3. SDS-PAGE analysis of sPLA synthesis after different2
 .chase periods. Plates 60 mm diameter were stimulated for 18 h
 .with IL-1b 1 nM and subsequently pulsed for 2 h with
w35 x  .S methioninercysteine 200 mCirml . The cells were chased
in medium with 1.5 mM unlabeled methionine and 1.25 mM
unlabeled cysteıne for different time-periods, lysed and anti-¨
sPLA immunoprecipitates were analyzed by SDS-PAGE and2
fluorography. For quantification appropriate gel areas were cut
out and counted in a scintillation counter.
labeled amino-acids present in the internal pool of rat
mesangial cells. The ungoing synthesis of radioactive
enzyme obscures the disappearance of the enzyme
pool present at the beginning of the chase. In order to
avoid this problem cycloheximide was added at the
start of the chase.
As can be seen in Fig. 4A pulse-labeled sPLA 2
protein in cells decreased as the chase time pro-
gressed. Quantification of immunoprecipitated 35S-
labeled sPLA was achieved by cutting out the ap-2
propriate gel areas and determination of radioactivity
in a scintillation counter. For the calculation of the
sPLA half-life we plotted the radioactivity in sPLA ,2 2
as percent of that present at ts0, on a log-scale
against time which yielded a straight line with a
 .  .correlation coefficient of 0.99 ns5 Fig. 4B . For
the decay curve a half-life of 2.4"0.3 h was calcu-
lated. However, after this rapid decrease 35S-labeled
sPLA could still be detected at a level correspond-2
ing to about 26% of the initial amount of radioactive
enzyme. Additional experiments showed that in con-
trol cells, not treated with IL-1b , hardly any 35S-
labeled sPLA was present, indicating that also this2
remaining pool of 26% corresponds to IL-1b-induced
 .sPLA data not shown . Most likely, sPLA disap-2 2
pearance from the cells is biphasic with a rapid first
phase and a much slower second phase. Considering,
that the rapidly disappearing pool constitutes approx.
74% of the total the half-life for disappearance of this
pool can be recalculated as the time point at which
37% rather than 50% of the total radioactivity has
disappeared from the cells. This calculation yields a
X  .value of t s1.6 h Fig. 4 .1r2
3.3. Secretion rate of sPLA from rat mesangial cells2
The half-life for disappearance of sPLA from2
mesangial cells as determined in the preceding para-
graph is likely to represent mainly secretion but could
potentially also involve intracellular turnover. To find
out how fast the induced sPLA was secreted from2
rat mesangial cells, we also performed immunopre-
cipitations with the anti-sPLA McAb on the culture2
medium of these cells. As can be seen from Fig. 5A
no further increase in the level of 35S-labeled sPLA 2
in the medium could be observed after a 1 h chase.
This was confirmed by quantifying the radioactivities
 .data not shown . In order to investigate the time
scale at which the enzyme is secreted more precisely
Fig. 4. Half-life of IL-1b-induced sPLA in rat mesangial cells.2
After 18 h stimulation by IL-1b , cells were pulsed for 2 h with
w35 xS methioninercysteine and chased for different time periods
 . after adding cycloheximide 10 mM and cold methionine 1.5
.  .mM and cold cysteine 1.25 mM . A. Representative quantita-
tive immunoprecipitation of 35S-labeled sPLA from cell ho-2
mogenates. B. From 5 independent experiments appropriate gel
areas were cut out and counted in a scintillation counter. The
radioactivity, as percent of that present at ts0, was plotted on a
log-scale against time for determination of t , the half-life of1r2
disappearance of sPLA from the cells.2
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Fig. 5. Rate of IL-1b-induced sPLA secretion into the culture2
medium. Cells were pulse-chased as described in the legend of
Fig. 4. After different chase times the medium was collected and
anti-sPLA immunoprecipitated, resolved on SDS-PAGE and2
analyzed by fluorography and radioactivity was determined of
appropriate gel areas. Percentage of sPLA released at each time2
point compared to the amount released at 1 h chase was calcu-
lated and plotted against time. A. Fluorograph of long chase
 .periods. B. The plot obtained after shorter chase times ns3 .
shorter chase periods were used. The amount of
sPLA released in the culture medium was quantified2
by cutting out appropriate gel areas and the release of
sPLA in the medium as percentage of the maximum2
found at ts1 h is plotted against time. From this
figure it can be concluded that the fast disappearance
of the enzyme out of the cells was at least partially
due to the secretion of sPLA in the culture medium.2
This process appears to be completed in 60 min Fig.
.5B . Thereafter, the amount of sPLA stayed con-2
 .stant for at least 3 h Fig. 5A .
4. Discussion
Group II PLA is believed to play a central role in2
w xthe process of inflammation 43 . Elevated levels of
sPLA activity are seen in association with chronic2
inflammatory disorders, such as rheumatoid arthritis,
and also with sepsis and septic shock. In studies with
cytokine expression after endotoxin challenge in ex-
w x w xperimental animals 44 and human volunteers 45
circulating IL-1 and TNF appeared within minutes
followed by PLA after a latency period of 1–3 h.2
While the mechanisms of induction of synthesis are
coming to light, the factors responsible for inactiva-
tion and removal of circulating extracellular PLA 2
are still unknown. Renal clearance of sPLA may2
play an important role since marked increases in
serum PLA are associated with uremia and end2
w xstage of renal failure 46,47 .
In order to get more insight in the time scale
during which sPLA remains to be synthesized and2
secreted from target cells after cytokine levels return
to basal levels in vivo, we investigated in model
experiments in vitro the net effect of ungoing produc-
tion and secretion or degradation of the enzyme in rat
mesangial cells after the IL-1b signal has been re-
moved. Fig. 1 showed that sPLA activity and pro-2
tein levels increased up to about 8 h in the culture
medium of mesangial cells. Thus, the IL-1b elicited
 .signal s to induce sPLA synthesis extinguish within2
a period of approx. 8 h. At that time point sPLA 2
mRNA levels have returned to near basal levels Fig.
.2 . After secretion the level of sPLA stayed constant2
 .for at least 48 h Fig. 1 . Studies examining the levels
of sPLA during the recovery phase of septic shock2
w xresulted in a circulating half-life of 32 h in man 48 .
However, for rat platelet PLA a half-life in the2
w xbloodstream was found of 30 s 49 . These authors
speculated that PLA was cleared by adsorption onto2
heparan sulfate proteoglycans on the endothelial sur-
face as such adsorptions were also found upon re-
lease of sPLA by cultured endothelial cells or upon2
w xadditon of purified sPLA to such cells 50 . This2
seemed not to be the case for sPLA secreted by2
mesangial cells.
Pulse-chase experiments revealed the newly syn-
thesized sPLA to be present in two distinct pools2
exhibiting widely different half-lifes. The half-life of
a rapidly disappearing pool of sPLA in rat mesan-2
 .gial cells is about 1.6 h Fig. 4 . The remaining pool
is too stable for meaningful determination of its
half-life since the chase experiments could only be
done in the presence of cycloheximide compare Fig.
.3 and longer term effects of cycloheximide on pro-
tein degradation cannot be excluded. In Fig. 5 it is
shown that secretion of sPLA from rat mesangial2
cells is a fast process which occurred within about 60
min, whereafter the levels of secreted sPLA in the2
 .culture medium stayed constant Figs. 1 and 5A .
When the rapidly disappearing pool consisted entirely
of enzyme destined for secretion the rate of disap-
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pearance should equal that of sPLA appearance in2
the medium. The latter appears to be faster, however,
and probably other unknown processes are involved.
It is not likely that the results are influenced because
enzyme is taken up again by cells and subsequently
degraded. In Fig. 1 the levels of sPLA in the culture2
medium did not change from 10 h up to 48 h. A
possible explanation for the discrepancy between the
half-life of sPLA in the cells and the secretion rate2
is the fact that there is some evidence that a consider-
able proportion of secretory proteins can be degraded
w xrather than secreted 51 .
With immunofluorescence we showed already that
the IL-1b-induced sPLA is present in the Golgi2
complex and in punctate structures presumably repre-
w xsenting secretory vesicles 52 . However, this does
not exclude the possibility that a part of the sPLA is2
present in another subcellular compartment, e.g.
w xmitochondrion 53 , and that it has a much longer
turnover rate in that compartment. Notably, our im-
w xmunofluorescence experiments 52 did not detect
sPLA on the cell surface, indicating that the se-2
creted enzyme does not bind to heparan sulfate pro-
teoglycans on mesangial cells as has been reported
w xfor endothelial and other cells 50 . Thus, the more
stable pool does not represent surface-bound enzyme.
It is known that mammalian pancreatic PLA 2
 . w xgroup I is synthesized as proenzyme 7 and in the
w xgene structure of human 12,54 and rat group II
w xPLA 55,56 a typical signal sequence is found.2
Therefore, type II PLA will be synthesized as a2
precursor form and will then be processed to a ma-
ture enzyme during or after translocation from the
cytoplasmic to luminal side of the endoplasmatic
reticulum. However, the zymogen form has never
been isolated at the protein level. In our experiments,
even when using shorter pulse times than the rou-
tinely applied 2 h, also no proenzyme was observed.
Either there is a fast conversion of the precursor to
the mature sPLA or the monoclonal antibody used2
does not recognize the proenzyme.
In summary, the present work has demonstrated
that the signals elicited by IL-1b to enhance sPLA 2
synthesis and secretion in mesangial cells extinguish
over a period of approximately 8 h upon withdrawal
of the cytokine stimulus. During this period the ele-
vated steady state levels of sPLA mRNA return to2
basal levels. These data suggest that the highly ele-
vated levels of circulating plasma sPLA as found2
under a large number of inflammatory conditions can
only remain produced as long as pro-inflammatory
cytokines circulate and during fairly short periods, for
rats up to 8 h, thereafter.
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